Circulating tumor cells (CTCs) detected in 37% of colorectal cancer patients with peritoneal metastases were associated with shorter recurrence-free and overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Patients with CTCs post-neoadjuvant treatment had significantly worse outcomes. Adjuvant therapy improved prognosis in CTC-positive patients but not in CTC-negative ones. CTCs may serve as a personalized biomarker for monitoring disease progression and predicting therapy response in this patient population.
Journal Article by Frühling P, Moberg L (…) Cashin PH et 4 al. in Int J Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.